智通财经APP获悉，荣昌生物(09995)再涨超9%，近三个交易日股价累涨超27%。截至发稿，涨9.26%，报18.4港元，成交额4012.51万港元。
消息面上，荣昌生物近日公布2024年前三季度业绩，营业收入约12.09亿元，同比增长57.1%；归属于上市公司股东的净亏损约10.71亿元，同比扩大3.96%。单计第三季度，公司实现营收4.7亿元，同比增长34.6%，其中，泰它西普实现2.7亿元销售，维迪西妥单抗实现2亿元销售；毛利率82.1%，同比提升5.8个百分点；亏损2.9亿元，较第二季度环比减少亏损32.6%。
浦银国际表示，荣昌生物三季度收入符合预期，净亏损显著好于预期，主要得益于研发费用管控显著好于预期。交银国际指出，未来一年内，泰它西普和维迪西妥有望在国内进一步扩大适应症获批范围、海外注册临床继续稳步推进。11.2亿元账上现金+28亿元授信额度足以支持公司在未达成BD交易的情况下维持近期运营。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.